- Home
- JBLU vs PHVS Comparison
JBLU vs PHVS Comparison
Compare JBLU & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBLU
- PHVS
- Stock Information
- Founded
- JBLU 1998
- PHVS 2015
- Country
- JBLU United States
- PHVS Switzerland
- Employees
- JBLU N/A
- PHVS N/A
- Industry
- JBLU Air Freight/Delivery Services
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- JBLU Consumer Discretionary
- PHVS Health Care
- Exchange
- JBLU Nasdaq
- PHVS Nasdaq
- Market Cap
- JBLU 1.6B
- PHVS 1.3B
- IPO Year
- JBLU N/A
- PHVS 2021
- Fundamental
- Price
- JBLU $5.02
- PHVS $21.17
- Analyst Decision
- JBLU Sell
- PHVS Buy
- Analyst Count
- JBLU 11
- PHVS 6
- Target Price
- JBLU $4.97
- PHVS $36.67
- AVG Volume (30 Days)
- JBLU 19.4M
- PHVS 194.9K
- Earning Date
- JBLU 07-29-2025
- PHVS 08-12-2025
- Dividend Yield
- JBLU N/A
- PHVS N/A
- EPS Growth
- JBLU N/A
- PHVS N/A
- EPS
- JBLU N/A
- PHVS N/A
- Revenue
- JBLU $9,138,000,000.00
- PHVS N/A
- Revenue This Year
- JBLU N/A
- PHVS N/A
- Revenue Next Year
- JBLU $7.77
- PHVS N/A
- P/E Ratio
- JBLU N/A
- PHVS N/A
- Revenue Growth
- JBLU N/A
- PHVS N/A
- 52 Week Low
- JBLU $3.34
- PHVS $11.51
- 52 Week High
- JBLU $8.31
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- JBLU 64.71
- PHVS 54.76
- Support Level
- JBLU $4.22
- PHVS $19.56
- Resistance Level
- JBLU $5.20
- PHVS $21.76
- Average True Range (ATR)
- JBLU 0.23
- PHVS 1.12
- MACD
- JBLU 0.08
- PHVS -0.06
- Stochastic Oscillator
- JBLU 83.65
- PHVS 67.14
About JBLU JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.